01 November 2007
A Simplified Premedication Protocol for One-Hour Paclitaxel Infusion in Various Combinations
Christos Kosmas, Nicolas TsavarisMed Sci Monit 2006; 12(11): CR462-466 :: ID: 462697
Abstract
Background: Many investigations have focused on optimal doses/schedules since regulatory agency approval of paclitaxel (Taxol). Paclitaxel is generally administered at doses of 175–225 mg/m[sup]2[/sup] over 3 hours or 135–175 mg/m[sup]2[/sup] over 24 hours, every 3 weeks. The purpose of this study was to simplify administration
and render it suitable and practical in the outpatient setting. Using this rationale, the duration
of administration was decreased to one hour, with a minimized premedication regimen.
Material/Methods: One hundred patients who were to receive paclitaxel-based chemotherapy combinations entered the study. Tumor types were non-small-cell lung cancer (NSCLC, n=40), small-cell lung cancer (SCLC, n=18), breast cancer (n=12), head and neck cancer (n=16), and ovarian cancer (n=14). Sixty patients received paclitaxel at 175 mg/m[sup]2[/sup] and the remaining 40 at 225 mg/m[sup]2[/sup]. The premedication regimen consisted of a single dose of dexamethasone 20 mg, dimethindene maleate (Fenistil)
4 mg, and ranitidine (Zantac) 50 mg, followed by the standard antiemetic therapy. Paclitaxel was
always administered before other chemotherapeutic agents, i.e. ifosfamide and/or platinum compounds,
except for breast cancer, where epirubicin preceded paclitaxel administration.
Results: Hypersensitivity reactions were recorded in 7 patients (7.0%) and were not infl uenced by age, gender, disease, dose schedule, or cycles of therapy. No serious adverse events were observed.
Conclusions: The simplifi ed administration dose schedule for paclitaxel is safe and accommodates its combination with other cytostatic agents.
Keywords: Antineoplastic Agents, Phytogenic - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Dexamethasone - administration & dosage, Dimethindene - administration & dosage, Neoplasms - drug therapy, Paclitaxel - administration & dosage, Premedication, Ranitidine - administration & dosage, Time Factors
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
08 Mar 2024 : Clinical Research
Evaluation of Foot Structure in Preschool Children Based on Body MassMed Sci Monit In Press; DOI: 10.12659/MSM.943765
15 Apr 2024 : Laboratory Research
The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in OsteoarthritisMed Sci Monit In Press; DOI: 10.12659/MSM.943738
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
08 Mar 2024 : Animal Research
Modification of Experimental Model of Necrotizing Enterocolitis (NEC) in Rat Pups by Single Exposure to Hyp...Med Sci Monit In Press; DOI: 10.12659/MSM.943443
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952